14. The use of claim 13, wherein the tumor associated antigen is selected from the group consisting of prostatic acid phosphatase, prostate specific antigen, NKX3.1, or prostate specific membrane antigen, PRAME; BAGE; RAGE, NY-ESO-1, SAGE, HAGE, Plu-1, HASH -1, HasH-2, Cripto, Criptin, MART-1/Melan-A, gp100, gp75, mda-7, tyrosinase, tyrosinase-related protein, p53, Ras, c-Myc, A-Raf, B-Raf, and C-Raf, MAGE-A1, MAGEA2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, MART-1, DAM-6, -10, GAGE-1, GAGE -2, GAGE -8, GAGE-3, GAGE -4, GAGE -5, GAGE -6, GAGE -7B, NA88-A, MART-1, MC1R, Gp100, PSM, TRP-1, TRP-2, ART-4, CAMEL, CEA, Cyp-B, hTERT, hTRT, iCE, MUC1, MUC2, P15, RU1, RU2, SART-1, SART-2, SART-3, Wilms' tumor antigen (WT1), AFP, β-catenin/m, Caspase-8/m, CEA, CDK-4/m, ELF2M, GnT-V, G250, HSP70-2M, HST-2, KIAA0205, MUM-1, MUM-2, MUM-3, Myosin/m, TRP-2/INT2, 707-AP, Annexin II, CDC27/m, TPI/mbcr-abl, BCRABL, interferon regulatory factor 4 (IRF4), ETV6/AML, LDLR/FUT, Pml/RAR, Tumor associated calcium signal transducer 1 (TACSTD1) TACSTD2, Epidermal Growth Factor receptor (EGFR and EGFRvIII), platelet derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR), integrin-linked kinase (ILK), STAT3, STAT5, STAT6, HIF-1, HIF-2, Nuclear Factor-Kappa B (NF-κB), Notch1-4, c-Met, mammalian targets of rapamycin (mTOR), WNT, PMSA, PR-3, MDM2, Mesothelin, renal cell carcinoma – 5T4, SM22-alpha, carbonic anhydrases I (CAI) and IX (CAIX) (also known as G250), STEAD, TEL/AML1, GD2, proteinase3, hTERT, sarcoma translocation breakpoints, EphA2, ML-IAP, EpCAM, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, ALK, androgen receptor, cyclin B1, polysialic acid, MYCN, RhoC, GD3, fucosyl GM1, mesothelian, PSCA, sLe, PLAC1, GM3, BORIS, Tn, GLoboH, NY-BR-1, RGs5, SART3, STn, PAX5, OY-TES1, sperm protein 17, LCK, HMWMAA, AKAP-4, SSX2, XAGE 1, B7H3, legumain, TIE2, Page4, MAD-CT-1, FAP, MAD-CT-2, and fos related antigen 1.

15. The use of claim 14, wherein the first immunogen is NY-ESO-1, MAGE A3, SSX2, or EGFRvIII.

16. The use of any one of claims 7-11, wherein each of the first immunogen and the second immunogen is a tumor associated antigen.

17. The use of claim 12, wherein the infectious disease organism is a virus.

18. The use of claim 17, wherein the virus is Herpes Simplex Virus-2 (HSV-2).